Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio The Motley Fool 2 days
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation The Motley Fool 3 days
Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer’s Drug Investor's Business Daily 4 days
Approval of Eli Lilly’s New Alzheimer’s Drug Will Accelerate New Era of Treatment The Wall Street Journal 4 days
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You? The Motley Fool 4 days